Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer Authors: Lan Lei, Madison Canning, Elizabeth Sakach, Almeera Lateef, Larisa Kamga, Minaam Abid, Kevin Kalinsky, Shipra Gandhi Published: 2026 ABSTRACT AbstractHormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for approximately 70% of breast cancer cases. Despite recent advances with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), resistance inevitably develops, often driven by activation of the phosphatidylinositol 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway. Genetic alterations such as PIK3CA mutations (present in ~ 45% of HR+/HER2- tumors), AKT1 mutations, and PTEN loss contribute to endocrine resistance and poor outcomes. This review summarizes emerging strategies targeting this pathway to overcome resistance in advanced disease. Isoform-specific PI3K inhibitors, including alpelisib and inavolisib, have demonstrated clinically meaningful progression-free survival benefits in PIK3CA-mutated populations, with inavolisib showing improved tolerability and efficacy. In contrast, pan-PI3K inhibitors such as buparlisib have been constrained by toxicity. Targeting downstream signaling, AKT inhibitors have also shown benefit: capivasertib has demonstrated clinical efficacy leading to US Food and Drug Administration approval, while ipatasertib has yielded encouraging results, particularly in tumors harboring PIK3CA, AKT1, or PTEN alterations. Mammalian target of rapamycin inhibitors, notably everolimus, have shown efficacy irrespective of mutation status. The dual PI3K-mTOR inhibitor (gedatolisib) has also shown promising progression-free survival benefit in a PIK3CA wild-type population. Next-generation agents, including mutant-selective PI3Kα inhibitors and bi-steric mTOR complex 1 inhibitors, are under active investigation. Optimal sequencing of these agents alongside endocrine therapy and CDK4/6i options remain a critical question, as does integration of genomic testing to guide therapy. Future directions include rational combination strategies, improved biomarker-driven selection, and novel modalities such as proteolysis-targeting chimeras (PROTACs). Collectively, these advances aim to enhance durability of response, minimize toxicity, and improve survival in HR+/HER2- metastatic breast cancer. Key Points Endocrine therapy combined with cyclin-dependent kinase 4/6 inhibitors remains the standard first-line treatment for endocrine-sensitive hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. In endocrine-resistant disease, the addition of inavolisib to fulvestrant and palbociclib represents a new standard of care; however, both estrogen receptor-dependent and estrogen receptor-independent resistance mechanisms continue to necessitate the development of targeted therapeutic strategies.The phosphatidylinositol 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway is a pivotal driver of endocrine resistance in HR+/HER2- breast cancer, underscoring its significance as a therapeutic target for combination strategies aimed at improving clinical outcomes.Future strategies include next-generation PI3K-AKT-mTOR inhibitors, dual inhibitors, rational combinations with immunotherapy, and novel approaches such as proteolysis-targeting chimeras (PROTACs) are promising in overcoming resistance and enhancing long-term outcomes. Introduction Breast cancer remains the most commonly diagnosed malignancy among women and the second leading cause of cancer-related mortality globally [1]. The hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) subtype accounts for approximately 70% of all breast cancer cases [2]. Despite this high prevalence of HR+/HER2- metastatic breast cancer, therapeutic advances were historically limited until the early 2000s, with the later approval of the cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in 2015. Efforts are now focused on the best approach(es) for patients after progression on CDK4/6i or potentially in combination with CDK4/6i. A critical unmet need remains for better targeted therapy options with durable response and favorable toxicity profiles in the setting of resistance to first-line treatment. This article systematically reviews emerging strategies targeting the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway in HR+/HER2‑ advanced breast cancer in the post‑CDK4/6 inhibitor era. Relevant literature was comprehensively identified from peer‑reviewed biomedical databases, with prioritization of PubMed/MEDLINE, major oncology journals, and abstracts from key international meetings (ASCO, ESMO, SABCS). Emphasis was placed on phase I–III clinical trials, pivotal translational studies, and high‑impact reviews published over the past two decades. Search terms included combinations of PI3K, AKT, mTOR, PIK3CA, AKT1, PTEN, HR+/HER2‑ breast cancer, endocrine resistance, and the names of investigational and approved targeted agents. Reference lists of selected articles were manually reviewed to identify additional relevant studies. Evidence was synthesized qualitatively, prioritizing studies with robust clinical endpoints, well‑defined molecular populations, and relevance to contemporary treatment paradigms. Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin (PI3K-AKT-mTOR) Pathway Biology Currently, the standard first-line treatment for patients with endocrine-sensitive HR+/HER2- advanced or metastatic breast cancer is endocrine therapy combined with a CDK4/6i, regardless of PIK3CA, AKT1, or PTEN mutation status. This standard of care is recommended by the consistent clinical benefit observed across key studies including PALOMA-3 [3], MONARCH 2 [4], and MONALEESA-3 [5]. These trials demonstrated a clinically significant median progression-free survival (mPFS) benefit irrespective of PIK3CA mutation status regardless of the endocrine therapy backbone [3, 6, 7]. Moreover, landmark trials such as MONALEESA-3 and MONALEESA-7 also demonstrated overall survival (OS) benefit in addition to mPFS gains [5, 8]. In endocrine-resistant, PIK3CA-mutated advanced disease, the addition of inavolisib to fulvestrant and palbociclib represents a new standard of first-line care following the INAVO-120 trial, which demonstrated significant clinical benefits across all key endpoints with this regimen, including mPFS and OS [9]. One of the mechanisms contributing to resistance to first-line CDK4/6i is dysregulation of the PI3K-AKT-mTOR pathway, which plays a pivotal role in regulating cell proliferation, metabolism, and survival [10]. Genetic aberrations affecting this axis are among the most common mechanisms of truncal mutation in HR+/HER2- breast cancers, occurring in approximately 40–50% of advanced cases [11]. PI3Ks constitute a broad family of lipid kinases classified into three groups, Class I, II, and III, with Class I being most relevant to tumorigenesis [12]. These kinases are activated by receptor tyrosine kinases and G-protein-coupled receptor, and downstream PI3K converts phosphatidylinositol-4,5 biphosphate to phosphatidylinositol-3,4,5-triphosphate [13]. PIP3 subsequently recruits AKT, which is catalyzed and activated by phosphoinositide-dependent protein kinase 1 and mTOR complex 2. Activated AKT regulates a host of proliferative effectors, including mTOR complex 1 (mTORC1), which controls protein synthesis, metabolism, and cell-cycle progression (Fig. 1) [10]. Activation of the phosphatidylinositol 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway. CDK4/6 cyclin-dependent kinases 4 and 6, E estrogen, ER estrogen receptor, E2F transcription factor, mTORC1 mammalian target of rapamycin complex 1, mTORC2 mammalian target of rapamycin complex 2, PDK1 3-phosphoinositide-dependent protein kinase-1, PIP2 phosphatidylinositol 4,5-bisphosphate, PIP3 phosphatidylinositol (3,4,5)-trisphosphate, PTEN phosphatase and tensin homolog, RB1 retinoblastoma protein, RTK receptor tyrosine kinase. Figure 1 was generated using BioRender software A frequently observed oncogenic alteration in this pathway is the gain-of-function mutation in the PIK3CA gene, which encodes the catalytic subunit p110α of PI3K. Approximately 45% of HR+/HER2- patients with metastatic breast cancer harbor these mutations according to SOLAR-1 trial [14], predominantly at the E542K and E545K (helical domain) or H1047R/L (kinase domain) hotspots [15]. Such mutations enhance PI3K activity, which promotes uncontrolled cellular proliferation and subsequently confers resistance to apoptosis [15]. Similarly, activating mutations in AKT1, present in ~ 7% of HR+/HER2– tumors, lead to downstream hyperactivation of mTOR signaling, which contributes to endocrine resistance [16]. Loss of PTEN, a tumor suppressor that counteracts PI3K signaling by dephosphorylating phosphatidylinositol-3,4,5-triphosphate to phosphatidylinositol-4,5 biphosphate, also results in unchecked pathway activity and therapeutic failure [10]. Many clinical trials targeting this signaling pathway have been conducted in an HR+ population and Table 1 summarizes critical results from pivotal and promising trials that have had or will have a practice changing impact. Table 1Key phase III clinical trials of phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin inhibitors for locally advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative BCTrial IDTreatment arms (n)PopulationBiomarkerMedian PFS(months, HR, 95% CI)US FDA approvalPivotal trials SOLAR-1 [14]Alpelisib + fulvestrant vs placebo + fulvestrantAdvanced/metastatic BC w/ PD on or after ET (HbA1C < 6.4%)PIK3CA11.0 vs 5.7 in PIK3CA-mutated patients (0.65, 0.5–0.9)Yes INAVO-120 [9]Inavolisib + palbociclib + fulvestrant vs placebo + palbociclib + fulvestrantPIK3CA-mut advanced/metastatic BC w/ PD on or within 12 mos of completing adjuvant ET (HbA1C < 6%)–15 vs 7.3 (0.43, 0.3–0.6); OS (HR 0.64, 95% CI 0.4–1.0)Yes Capitello-291 [67]Capivasertib + fulvestrant vs placebo + fulvestrantAdvanced/metastatic BC w/ PD on AI ± CDK4/6i (HbA1C < 8%)PIK3CA, AKT, PTEN7.3 vs 3.1 in AKT pathway-altered patients (0.50, 0.4–0.7)Yes Bolero-2 [75]Everolimus + exemestane vs placebo + exemestaneAdvanced BC w/ recurrence on or within 12 mos of adjuvant AI or PD during or within 1 mo of AI completionNone7.8 vs 3.2 (0.4–0.5)YesPromising ongoing trials VIKTORIA-1 [82]Gedatolisib + fulvestrant + palbociclib vs gedatolisib + fulvestrant + placeboAdvanced/metastatic BC w/ PD on or after AI + CDK 4/6iPIK3CAOngoingNo FINER [73]Ipatasertib + fulvestrant vs placebo + fulvestrantMetastatic BC PD on 1st line AI + CDK4/6iPIK3CA, AKT, PTEN5.3 vs 2.0 (0.61, 0.5–0.8) in overall and 5.5 vs 1.9 (0.47, 0.3–0.7) in AKT pathway-altered patientsNoAI aromatase inhibitor, BC breast cancer, CDK4/6i cyclin-dependent kinases 4 and 6 inhibitor, CI confidence interval, ET endocrine therapy, FDA Food and Drug Administration, HbA1C glycated hemoglobin, HR hazard ratio, mos months, OS overall survival, PD progression of disease, PFS progression-free survival Key phase III clinical trials of phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin inhibitors for locally advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative BC AI aromatase inhibitor, BC breast cancer, CDK4/6i cyclin-dependent kinases 4 and 6 inhibitor, CI confidence interval, ET endocrine therapy, FDA Food and Drug Administration, HbA1C glycated hemoglobin, HR hazard ratio, mos months, OS overall survival, PD progression of disease, PFS progression-free survival Role of PI3K-AKT-mTOR Signaling in Endocrine-Resistant Breast Cancer The three key oncogenic pathways that drive HR+ locally advanced and metastatic breast cancer, including estrogen receptor (ER), CDK4/6, and the PI3K signaling axes, are highly intertwined and encompass complex feedback mechanisms [15, 17–19]. In an in vitro study, Miller et al. demonstrated that long-term estrogen-deprived HR+ breast cancer cells exhibit compensatory hyperactivation of PI3K signaling, implicating this pathway as a mechanism of resistance to anti-estrogen therapy [18]. Similarly, Herrera-Abreu et al. showed that dual inhibition of CDK4/6 and PI3K in patient-derived xenograft models induced synergistic apoptosis and tumor regression, supporting the rationale for combination regimens targeting multiple channels within this network [17]. Additionally, whole-exome sequencing studies by Wander et al. identified at least eight mechanisms of resistance to CDK4/6i, including activating alterations in AKT1 [19]. Further evidence from the PALOMA-3 trial revealed clonal evolution characterized by emergent PIK3CA and ESR1 mutations following treatment with fulvestrant alone or in combination with palbociclib [20]. Notably, resistance was accelerated in the monotherapy arm, reinforcing the need for combination therapeutic strategies [20]. Evaluating the real-world prevalence of PI3K-AKT-mTOR pathway mutations, a recent Flatiron Health-based retrospective study showed that at least one PIK3CA/AKT1/PTEN alteration was detected in 55% of the tested population with HR+/HER2– metastatic breast cancer [21]. These findings underscore the PI3K-AKT-mTOR pathway as a central mediator of resistance in HR+/HER2– breast cancer. The development of pathway-specific inhibitors, particularly when combined with endocrine therapy and CDK4/6 blockade, represents a promising approach to overcoming endocrine resistance and improving patient outcomes for metastatic HR+/HER2– disease. Resistance Mechanisms to the PI3K-AKT-mTOR Pathway Resistance to PI3K pathway inhibition in breast cancer arises through interconnected mechanisms broadly classified as on-target pathway reactivation and off-target compensatory signaling [10, 22–24]. On-target reactivation involves restoration of PI3K-AKT-mTOR signaling despite pharmacologic inhibition, commonly through PTEN alterations, which may be intrinsic or acquired. PTEN loss shifts signaling dependence from the p110α isoform (targeted by alpelisib and inavolisib) to p110β, thereby bypassing α-selective inhibition [25, 26]; additionally, PI3K inhibition may paradoxically inactivate PTEN via a USP10–GSK3β axis, creating a feedback loop that limits pathway suppression [27]. In a phase I trial of alpelisib (NCT01870505), loss-of-function PTEN mutations were observed in ~ 25% of patients with de novo resistance [28], highlighting the potential role of PTEN loss as a mechanism of primary resistance. Varkaris et al. further demonstrated that acquired genomic alterations within the PI3K pathway emerge in up to 50% of patients following alpelisib exposure, including PTEN loss and activating AKT1 mutations [24]. Importantly, this study also highlights a potentially significant role for secondary PIK3CA mutations as a driver of acquired resistance to PI3Kα inhibitors. While prior studies suggested that secondary PIK3CA mutations may increase sensitivity to PI3Kα inhibition, Varkaris et al. demonstrated that specific secondary mutations can alter the inhibitor-binding pocket, thereby conferring resistance to orthosteric PI3Kα inhibitors. Notably, this resistance could be overcome by a novel allosteric pan-mutant-selective PI3Kα inhibitor RLY-2608. Approach to Genomic Testing in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Metastatic Disease Clinical Adoption of PIK3CA Testing in HR+ Advanced Breast Cancer Over the past two decades, the PI3K-AKT-mTOR pathway has been recognized as a key driver of tumorigenesis in solid malignancies. Somatic missense mutations in PIK3CA were first identified in colorectal cancer and later found to be prevalent in breast, brain, liver, stomach, and lung malignancies [29]. In a larger breast tissue cohort, Bachman et al. demonstrated that PIK3CA is the most frequently mutated oncogene in breast cancer, irrespective of ER/progesterone receptor/HER2 status or nodal involvement [30]. Later analyses refined these findings, showing that PIK3CA mutations are most common in ER-positive subtypes [31]. Despite these discoveries, the absence of validated biomarkers or targeted therapies initially delayed clinical adoption of PIK3CA-directed testing. In 2015, ASCO guidelines recommended against routine next-generation sequencing (NGS) in metastatic breast cancer, citing that “NGS of tumors has not demonstrated clinical utility” [32]. By 2022, an expert panel update recommended that all patients with HR+/HER2– metastatic or locally recurrent breast cancer undergo PIK3CA testing using NGS of either circulating tumor (ctDNA) or tumor tissue [33]. This shift was driven by the SOLAR-1 trial [34], which determined mutation status using the therascreen® PIK3CA RGQ PCR Kit (Qiagen), a US Food and Durg Administration (FDA)-approved real-time polymerase chain reaction (PCR) assay that detects 11 predefined “hotspot” mutations (later termed the SOLAR1m panel). Hotspot Versus Comprehensive Profiling Subsequent analyses explored the limitations of hotspot-only testing used in SOLAR-1 and evaluated broader sequencing approaches. A follow-up study compared the original SOLAR-1 hotspot panel (SOLAR1m) with comprehensive genomic profiling that covers the entire PIK3CA coding sequence. In tissue biopsies, PIK3CA mutations were identified in about 35% of samples, including 7% that carried only non-hotspot variants without concurrent SOLAR1m [35]. In paired tissue and liquid biopsies, liquid testing showed 77% positive percent agreement with tissue overall, which improved to 95% when ctDNA fraction was ≥ 2% and reached 100% sensitivity at ≥ 10% ctDNA fraction. By contrast, the therascreen assay demonstrated a sensitivity of 86% for SOLAR1m mutations but only 70% when considering all PIK3CA variants, reflecting its inability to detect non-hotspot alterations [35]. Expanding testing beyond hotspot regions captured an extra 20–30% of patients with OTHERm, underscoring the potential clinical impact of broader testing strategies. Supporting this, Martínez-Sáez et al. reported that while the majority of PIK3CA mutations cluster in well-known hotspots (H1047R, E545K, E542K), a meaningful subset occur in less frequent loci [36]. Therapeutic relevance, however, appears to differ. Rugo et al. confirmed clear benefit from alpelisib plus fulvestrant in patients with SOLAR1m, whereas responses in OTHERm-only tumors were limited [35]. Some activity was observed in patients whose tumors carried both SOLAR1m and OTHERm, suggesting that mutation co-occurrence may influence treatment response. Overall, these findings demonstrate that comprehensive genomic profiling improves mutation detection without compromising hotspot sensitivity, though further validation is needed to determine the predictive value of OTHERm for PI3K-targeted therapies. Comparative Performance of NGS Platforms It remains unclear how current commercially available NGS platforms perform comparatively, and no standardized guideline exists for choosing between primary tumor, metastatic tumor, or ctDNA, each of which has limitations such as poor-quality archived tissue or low ctDNA fraction [37]. Updated recommendations for PIK3CA testing at disease progression have highlighted the urgent need for accurate targeted mutation detection. The Hellenic Cooperative Oncology Group recently showed that NGS is more sensitive than Sanger sequencing/quantitative PCR, with only 8.8% discordance in 235 patients with known PIK3CA positivity [38]. Most recently, Chaki et al. compared tissue-based FoundationOne®CDx and blood-based FoundationOne®Liquid CDx with a focus on PIK3CA detection [39]. They reported that blood-based NGS achieved high concordance for PIK3CA mutations when the ctDNA fraction was ≥ 1%, with positive percent agreement > 93% at ≥ 10% ctDNA and 96% at 1–10% ctDNA, but sensitivity declined substantially when the ctDNA fraction was < 1% [39]. Importantly, a tissue biopsy captured about 10% more PIK3CA alterations than a liquid biopsy, underscoring its greater sensitivity; similar patterns were also observed for AKT1 and PTEN mutations. These findings support the use of blood-based NGS as a minimally invasive option for mutation detection, while reinforcing that negative results, particularly in the setting of a very low ctDNA fraction, should be confirmed with tissue-based testing [40]. In addition, several investigations have evaluated alternative PCR methods, including droplet digital PCR, which offers high sensitivity for detecting low-fraction ctDNA and enables expanded panels covering non-hotspot PIK3CA mutations [41–43]. Clinical Trial Integration Reflecting on these advances, the INAVO-120 phase III trial of inavolisib plus fulvestrant prospectively incorporated both ctDNA and tumor tissue testing for PIK3CA mutations to determine patient eligibility, acknowledging the complementary strengths of each approach while ongoing analyses aim to establish their optimal role in clinical practice. Taken together, these results highlight the urgent need for harmonized guidelines that integrate the strengths and limitations of both tissue- and blood-based testing strategies [9]. PI3K-AKT-mTOR Inhibitors for HR+/HER2– Breast Cancer Pan-PI3K inhibitors Pan-PI3K inhibitors target all class I PI3K isoforms, offering broad pathway inhibition, but at the cost of significant toxicity. Bystander effect on immune, metabolic, and gastrointestinal function creates a narrow therapeutic window. As a result, dose reductions are frequently required, which can compromise sustained tumor control. Moreover, early clinical trials conducted in unselected patient populations likely underestimate the therapeutic potential of these agents. Buparlisib Buparlisib, a pan‑PI3K inhibitor, was extensively evaluated in the BELLE clinical trials following encouraging preclinical and early‑phase results [18, 44, 45]. In the phase III BELLE‑2 trial, buparlisib plus fulvestrant modestly improved mPFS (6.9 months vs 5.0 months, hazard ratio [HR], 0.78; 95% confidence interval [CI] 0.67–0.89) compared with placebo plus fulvestrant in postmenopausal women with HR+/HER2– advanced breast cancer resistant to aromatase inhibitors (AIs) [46], both in the overall population and in tumors with PI3K pathway activation. The subsequent BELLE‑3 trial demonstrated a similar mPFS benefit in patients previously treated with endocrine therapy and mTOR inhibitors [47]. However, clinical benefit was limited by substantial toxicity, with high rates of dose reductions and treatment discontinuation, as well as notable psychiatric adverse events, likely related to central nervous system penetration [46, 47]. Because of these safety concerns and the modest efficacy, buparlisib did not advance into clinical practice. Isoform-Specific PI3K Inhibitors Taselisib Taselisib (GDC-0032) is an orally bioavailable, potent, and selective inhibitor of class I PI3K isoforms α, δ, and γ. Preclinical studies and early-phase clinical trials demonstrated its antitumor activity in patients with PIK3CA-mutated breast cancer, which led to the development of the SANDPIPER trial—a phase III study designed to evaluate the efficacy of taselisib plus fulvestrant versus placebo plus fulvestrant in both PIK3CA-mutant and wild-type populations [48]. The trial reported a statistically significant improvement in progression-free survival (PFS), with a median of 7.4 months (95% CI 7.26–9.07) in the taselisib arm compared with 5.4 months (95% CI 3.68–7.29) in the placebo arm (stratified HR 0.70; 95% CI 0.56–0.89; P = 0.0037). However, despite this statistical benefit, the modest clinical effect and an unfavorable safety profile have limited its clinical utility—this was highlighted by a 32% incidence of serious adverse events, most commonly gastrointestinal disorders that were life threatening, required/prolonged hospitalization, or resulted in significant disability, in the taselisib group compared with 8.9% in the placebo group. As a result, taselisib is not approved by regulatory agencies and will not be included in clinical practice. Alpelisib Alpelisib (BYL719) is the first studied oral inhibitor that selectively targets p110α [12, 49]. In the global phase III SOLAR-1 trial, alpelisib plus fulvestrant was compared to placebo plus fulvestrant in patients with HR+/HER2– advanced breast cancer who had previously received endocrine therapy [14]. The participants were stratified based on PIK3CA-mutation status. In patients with tumors that expressed the PIK3CA mutants, there was a statistically significant improvement in PFS with alpelisib plus fulvestrant compared with fulvestrant alone (mPFS: 11 months vs 5.7 months; HR 0.65, 95% CI 0.50–0.85; P < 0.001). In contrast, the cohort without PIK3CA mutations did not have a statistically significant outcome (mPFS: 7.4 months in the alpelisib plus fulvestrant group vs 5.6 months in the fulvestrant group; HR 0.85, 95% CI 0.58–1.25). The median OS did not reach statistical significance in either group [34]. This pivotal study led to the FDA approval of alpelisib with fulvestrant for patients with HR+/HER2–, PIK3CA-mutated, advanced or metastatic breast cancer. It is important to note, the proportion of patients who received first-line CDK4/6i in this study was relatively low (5.9%). To address this issue, the phase II BYLieve trial evaluated the efficacy of alpelisib in patients with PIK3CA-mutated, HR+/HER2− advanced breast cancer who progressed on prior CDK4/6i [50]. BYLieve was a non-randomized single-arm study consisting of three cohorts: Cohort A: alpelisib plus fulvestrant after progression on a CDK4/6i plus an AI; Cohort B: alpelisib plus an AI after progression on a CDK4/6i plus fulvestrant; Cohort C: alpelisib plus fulvestrant after progression on prior AI-based therapy (letrozole, fulvestrant, or CDK4/6i plus fulvestrant). With ≥ 18 months of follow-up, alpelisib plus endocrine therapy showed clinical activity across all cohorts: mPFS ranged from 5.6 to 8.0 months, and median OS ranged from 20.7 to 29.0 months following prior exposure to CDK4/6i, chemotherapy, or endocrine therapy [50]. Specifically, in Cohort A, 53.8% of the 119 patients achieved 6-month PFS with alpelisib plus fulvestrant, confirming the activity of alpelisib plus fulvestrant in the PIK3CA-mutated population post first-line CDK4/6i [51]. Furthermore, the ongoing phase III EPIK-B5 trial—a randomized, double-blind, placebo-controlled study evaluating alpelisib plus fulvestrant in patients with PIK3CA-mutated advanced breast cancer who have progressed following CDK4/6i and AI therapy—will provide additional evidence on the efficacy and safety of this regimen in the near future [52]. Inavolisib Inavolisib (RLY-2608) is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of PI3K, with a unique ability to promote the degradation of mutant p110α protein [53]. Preclinical and early clinical studies have demonstrated encouraging antitumor activity of inavolisib, both as monotherapy and in combination with standard-of-care agents, including in heavily pretreated patients and those with prior CDK4/6i exposure [53–57]. Notably, inavolisib has demonstrated a favorable therapeutic window with good tolerability when used in combination with CDK4/6i [56, 57]. Based on these promising data, the phase III, double-blind, randomized INAVO-120 trial evaluated first-line inavolisib in combination with palbociclib and fulvestrant versus placebo with palbociclib and fulvestrant in patients with HR+/HER2–, PIK3CA-mutated advanced or metastatic breast cancer who experienced disease recurrence during or within 12 months after completion of adjuvant endocrine therapy [9]. The study reported a mPFS of 15.0 months (95% CI 11.3–20.5) in the inavolisib group, compared with 7.3 months (95% CI 5.6–9.3) in the control arm (HR for disease progression or death, 0.43; 95% CI 0.32–0.59). Overall survival benefit was also observed in the intervention arm (34.0 months vs 27 months; HR for death, 0.67; 95% CI 0.48–0.94) [58]. Importantly, the enhanced selectivity and degradation capability of inavolisib contributes to its improved safety profile compared with alpelisib. Its broader therapeutic window may also reduce treatment discontinuation rates and improve long-term outcomes. These findings have led to the INAVO-121 trial, a head-to-head comparison of inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with PIK3CA-mutated, HR+/HER2– locally advanced or metastatic breast cancer after progression on a CDK4/6i and endocrine therapy combination [59]. This ongoing trial has the potential to bring another PI3K inhibitor to the forefront of the second-line metastatic space following progression on CDK4/6i–based therapy. Additionally, the INAVO123 trial is evaluating first-line inavolisib in combination with a CDK4/6i and letrozole versus a CDK4/6i plus letrozole in a similar PIK3CA-mutated population, which may provide further evidence to support its use in the frontline setting [60]. Pan-AKT Inhibitors Capivasertib Capivasertib (AZD5363) is a potent selective oral inhibitor of all three AKT isoforms (AKT1–3) that has demonstrated antitumor activity against HR+/HER2– breast cancer in both preclinical and clinical studies [61–63]. In xenograft models, sensitivity to capivasertib was enhanced when PIK3CA mutations co-occurred with PTEN loss or inactivation, suggesting synergistic effects through dual pathway disruption [64]. The NCI-MATCH subprotocol EAY131-Y non-randomized trial demonstrated that in patients with an AKT1 E17K-mutated tumor treated with capivasertib, a clinically significant objective response rate was achieved, including one complete response [65]. The phase II FAKTION trial further evaluated the combination of fulvestrant and capivasertib versus fulvestrant plus placebo in patients with HR+/HER2– advanced or metastatic breast cancer who had progressed on prior AIs [62]. This study demonstrated a significant improvement in PFS, with a median PFS of 10.3 months (95% CI 5.0–13.2) in the capivasertib arm versus 4.8 months (95% CI 3.1–7.7) in the placebo arm (HR, 0.58; 95% CI 0.39–0.84). In contrast, the phase II BEECH trial, which investigated capivasertib in combination with paclitaxel, did not demonstrate a PFS benefit [66]. Turner et al. attributed this to insufficient ER pathway inhibition, highlighting the importance of combining AKT or PI3K inhibitors with endocrine therapies such as AIs, fulvestrant, or novel agents like elacestrant to achieve meaningful clinical outcomes, as seen in FAKTION [66]. Building on these insights, the phase III CAPItello-291 trial was conducted to evaluate capivasertib plus fulvestrant versus placebo plus fulvestrant in patients with HR+/HER2– advanced or metastatic breast cancer who had relapsed or progressed on or after AI therapy [67]. Prior CDK4/6i exposure was permitted and occurred in the majority of patients (69.1%). In the PI3K pathway-altered population (defined by alterations in PIK3CA, AKT1, or PTEN), the combination therapy significantly improved mPFS (7.3 months vs 3.1 months; HR, 0.50; 95% CI 0.38–0.68). This benefit was also observed in the overall study population (7.2 months vs 3.6 months; HR, 0.6; 95% CI 0.51–0.71); however, an exploratory analysis of mPFS in the 313 (44%) patients whose tumors did not have a PIK3CA/AKT1/PTEN alteration showed a HR of 0.79 (95% CI 0.61–1.02), indicating that clinical improvement was driven primarily by these biomarker-positive tumors [67]. Based on these findings, the FDA approved capivasertib in combination with fulvestrant in November 2023 for the treatment of patients with HR+/HER2– locally advanced or metastatic breast cancer harboring one or more alterations in PIK3CA, AKT1, or PTEN, following progression on at least one line of endocrine therapy in the metastatic setting or recurrence during or within 12 months of adjuvant therapy [68]. To further expand on these results, CAPItello-292, an ongoing phase IB/III trial, is investigating the addition of capivasertib to fulvestrant and a CDK4/6i in the first-line metastatic setting for patients with HR+/HER2– disease who are CDK4/6i naïve in the metastatic setting [69]. Of note, the CAPItello-290 trial, which evaluated capivasertib in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative breast cancer, failed to meet the dual primary endpoints of improved OS in either the overall population or in the subgroup with PIK3CA/AKT1/PTEN-altered tumors. The future development strategies of capivasertib will therefore focus on HR+ disease [70]. Ipatasertib Ipatasertib is a potent and selective AKT inhibitor that has demonstrated efficacy and safety in both preclinical models and early-phase human studies [71]. These promising findings led to the development of FAIM, a phase II, randomized, open-label trial that enrolled patients with HR+/HER2– advanced breast cancer who exhibited poor clearance of ctDNA at the end of the first cycle with palbociclib and fulvestrant [72]. The ongoing trial is investigating whether switching to ipatasertib in combination with palbociclib and fulvestrant improves PFS and OS in patients with high levels of ctDNA, compared to continuing palbociclib with fulvestrant alone. A separate phase III trial, FINER, evaluated the combination of ipatasertib and fulvestrant in patients with HR+/HER2– advanced breast cancer following progression on first-line therapy with a CDK4/6i and an AI [73]. The study reported a significant improvement in mPFS compared with placebo plus fulvestrant. While follow-up data and additional analyses are still pending, ipatasertib appears to be a promising selective AKT inhibitor that may offer a clinical benefit comparable to capivasertib in the second-line metastatic setting, with a similar side-effect profile of gastrointestinal disturbance with diarrhea and metabolic derangements with hyperglycemia. mTOR Inhibitors Temsirolimus Temsirolimus, another mTOR inhibitor, was evaluated in the HORIZON trial, a phase III study assessing letrozole plus temsirolimus versus letrozole plus placebo as first-line therapy in AI-naïve patients [74]. The study did not demonstrate a PFS benefit in the intervention arm (HR, 0.90; 95% CI 0.76–1.07). The lack of efficacy may be attributed to the study population, which consisted of endocrine therapy-naïve patients, a group in which estrogen deprivation alone is often highly effective. In retrospect, the absence of prior endocrine treatment may have limited the potential impact of mTOR inhibition in this setting. These findings underscore a broader principle observed across multiple studies: selection pressure from prior endocrine therapy appears to enhance tumor sensitivity to PI3K-AKT-mTOR pathway inhibitors. Everolimus Everolimus, a derivative of sirolimus, inhibits mTOR through allosteric binding to mTORC1 and was the first approved agent targeting the PI3K-AKT-mTOR pathway. In the pivotal BOLERO-2 trial [75], the combination of everolimus and exemestane was compared to placebo and exemestane in patients with HR+ advanced breast cancer who had experienced recurrence or progression during or after treatment with a non-steroidal AI, either in the adjuvant or metastatic setting. The study demonstrated a significant improvement in investigator-assessed PFS compared with exemestane alone (mPFS: 7.8 vs 3.2; HR 0.45, 95% CI 0.38–0.54; P < 0.0001). Unfortunately, the difference in OS was not statistically significant (median OS 31.0 vs 26.6; HR 0.89, 95% CI 0.73–1.10; P = 0.1426) [76, 77]. However, given its tolerability and favorable long-term safety profile, also supported by its use in organ transplantation and rare genetic disorders, the FDA approved everolimus in 2012 for the treatment of HR+/HER2– advanced breast cancer in combination with exemestane. Recent real-world observation also suggests that everolimus plus endocrine therapy can achieve a longer estimated mPFS of 6.0 months (95% CI 5.3–7.8) when compared with endocrine therapy only in patients with progression after CDK4/6i, with the most pronounced benefit in patients on previous CDK4/6i therapy lasting for > 18 months (mPFS 8.7 months, 95% CI 6.6–11.3) [78]. The recently published evERA trial investigated the combination of giredestrant and everolimus versus standard endocrine therapy with everolimus in patients with HR+/HER2– advanced breast cancer who experienced disease progression or relapse during/post-CDK4/6i with endocrine therapy. This trial showed that everolimus in addition to giredestrant, as compared with standard of care, achieved statistically significant and clinically meaningful improvements in investigator-assessed PFS (8.77 months vs 5.49 months; HR, 0.56; 95% CI 0.44–0.71), regardless of ESR1 mutation status [79]. PI3K-mTOR Dual Inhibitors Gedatolisib Gedatolisib is a dual PI3K-AKT-mTOR pathway inhibitor that targets class I PI3K isoforms as well as both mTOR subcomplexes, mTORC1 and mTOR complex 2, theoretically enhancing therapeutic efficacy by blocking compensatory signaling. This hypothesis was supported by phase Ib data in patients with HR+/HER2– advanced breast cancer, where the combination of gedatolisib with palbociclib and endocrine therapy demonstrated a promising objective response rate—85.2% in the first-line setting and 25.0–61.5% in second-line and later settings—compared to historical controls with standard-of-care regimens [80]. Building on these results, the phase III VIKTORIA-1 trial was initiated to evaluate intravenous gedatolisib (3 weeks on, 1 week off) and fulvestrant, with or without palbociclib, in patients with HR+/HER2– advanced breast cancer previously treated with any CDK4/6i in combination with a non-steroidal AI [81]. Patients without known PIK3CA mutations were enrolled into the Study 1 cohort and randomized to one of three arms: A (gedatolisib, palbociclib, and fulvestrant), B (gedatolisib and fulvestrant), or C (fulvestrant alone). Patients with confirmed PIK3CA mutations were enrolled into the Study 2 cohort and randomized to arm D (gedatolisib, palbociclib, and fulvestrant), E (alpelisib and fulvestrant), or F (gedatolisib and fulvestrant). VIKTORIA1 recently reported that patients in the triplet group (Study 1, arm A) and the doublet group (Study 1, arm B) both achieved the study’s two primary endpoints—the triplet group showed a 7.3-month incremental improvement in mPFS as compared with fulvestrant only (HR, 0.24; 95% CI 0.17–0.35), and the doublet cohort achieved a 5.4-month mPFS as compared with arm C (HR, 0.33; 95% CI 0.17–0.35) [82]. This trial is expected to help refine treatment sequencing strategies in this setting. In parallel, the ongoing phase III VIKTORIA-2 trial is evaluating gedatolisib in combination with a CDK4/6i and fulvestrant as a first-line treatment in patients with HR+/HER2– advanced breast cancer who are endocrine therapy resistant, similar to the INAVO-120 population. Rising PI3K-AKT-mTOR Agents The PI3K-AKT-mTOR pathway remains one of the most intensively studied targets in efforts to overcome breast cancer relapse and progression. Numerous agents have advanced into phase III clinical trials, including those previously discussed, as well as additional compounds evaluated in phase II studies, such as pictilisib (a pan-PI3K inhibitor) [83], MK-2206 (a selective allosteric AKT inhibitor) [84], and voxtalisib (a potent inhibitor of all four class I PI3Ks and a weaker inhibitor of mTOR) [85]. Despite early promise, many of these agents ultimately failed in both the adjuvant and metastatic settings over the past two decades. The main reasons for these setbacks include unacceptable toxicity profiles, particularly gastrointestinal adverse events, hyperglycemia, and fatigue, alongside resistance mechanisms such as PTEN loss and activation of compensatory signaling pathways. Additionally, the absence of biomarker-guided patient selection and the lack of demonstrated synergy in combination regimens contributed to disappointing outcomes. In response, the new generation of PI3K-AKT-mTOR inhibitors has been developed to address these limitations, with several now under investigation in phase I clinical trials. Allosteric inhibitors are mechanistically distinct from conventional ATP‑competitive (orthosteric) PI3K inhibitors (e.g., alpelisib). They bind a mutation‑induced cryptic pocket that is spatially distinct from the ATP‑binding site and accessible only in mutant p110α conformations, thereby conferring mutant selectivity [57, 86, 87]. As a result, these agents potently inhibit oncogenic PI3Kα variants (H1047R, E542K, E545K) while largely sparing wild‑type PI3Kα. In contrast, covalent PI3Kα inhibitors or degraders not only retain orthosteric inhibitory activity but also induce selective proteasomal degradation of mutant p110α via a receptor tyrosine kinase (HER2)-dependent mechanism [88]. RLY-2608, STX-478, and LOXO-783 are allosteric mutant-selective inhibitors of PI3Kα designed to spare the wild-type receptor, thereby reducing the risk of treatment-induced hyperglycemia as demonstrated in preclinical studies [57, 86, 87]. TOS-358, a first-in-class covalent PI3Kα inhibitor, has shown antitumor activity at low doses with minimal toxicity [88]. ALTA2618 is an oral allosteric AKT1 E17K mutation-selective inhibitor that selectively, covalently, and potently inhibits the AKT1 E17K variant. This agent exhibits approximately 24-fold and at least 236-fold greater selectivity for AKT1 E17K over AKT1 (with wild-type E17) and AKT2 E17K, respectively, and has demonstrated potent, dose-dependent, and prolonged anti-tumor activity in xenograft models [89]. Currently, the ALTive-001 phase I/Ib trial is evaluating the safety and tolerability of ALTA2618 [89]. RMC-5552, a bi-steric selective mTORC1 inhibitor that combines a rapamycin-like moiety with an active-site mTOR inhibitor, achieves greater than 25-fold selectivity for mTORC1 over mTOR complex 2 substrates and has demonstrated single-agent antitumor activity in xenograft models of PIK3CA-mutant breast cancer [90], which now has advanced to a first-in-human, phase I/Ib, clinical trial for patients with advanced solid tumors [91]. Toxicity and Tolerance of PI3K-AKT-mTOR Inhibitors Despite the increasing role of inhibitors targeting the PI3K-AKT-mTOR pathway in endocrine-driven HR+ metastatic breast cancer, clinical application of these agents has revealed substantial toxicities, often requiring dose reductions or treatment discontinuation (Table 2). Grade 3 toxicities, defined as medically significant but not life threatening, and grade 4 toxicities, considered life threatening, have been commonly observed with PI3K-AKT-mTOR pathway inhibitors. The most frequently reported grade 3 toxicities include hyperglycemia, maculopapular rash, and diarrhea [14, 47, 48, 67, 73]. In the SOLAR-1 trial, nearly 25% of participants discontinued treatment because of adverse events [14]. Hyperglycemia and rash were the most common intolerable side effects, affecting approximately 35% of patients. Dose reductions were required in 25.7% of patients, compared with just 2.5% in the placebo group. Subsequent studies have evaluated mitigation strategies. The METALLICA trial showed that pre-treatment with metformin significantly reduced hyperglycemia, and prophylactic antihistamines such as cetirizine have been used to manage rash. Both the above strategies were associated with improved overall tolerability [92]. Table 2Major AEs observed in pivotal phase III trials of phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin inhibitorsSOLAR-1 [14]INAVO-120 [9]CAPItello-291 [67]BOLERO-2 [75]Regimen (n)Alpelisib + fulvestrant (284)Inavolisib + fulvestrant + palbociclib (161)Capivasertib + fulvestrant (355)Everolimus + exemestane (482)Most common AEs (%), grade ≥ 3 Hyperglycemia36.65.62.3<5.0 Diarrhea/nausea6.7/2.53.7/0.69.3/0.8<3.0/<2.0 Rash9.90.012.11.0 Stomatitis and mucosal inflammation4.65.62.08.0 OthersWeight loss (3.9)Neutropenia (80.2)Anemia (6.2)Thrombocytopenia (14.2)Anemia (2.0)Anemia (5.0)Grade ≥ 3 AEs (n, %)216 (76.1)149 (92.0)152 (42.8)111 (23.0)Dose modification or treatment interruption because of AEs125 (74.0)134 (82.7)Reduction: 70 (19.7)Interruption: 124 (34.9)N/ATreatment discontinuation because of AEs71 (25.0)11 (6.8)46 (13.0)92 (19.0)AEs adverse events, N/A no data available Major AEs observed in pivotal phase III trials of phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin inhibitors Neutropenia (80.2) Anemia (6.2) Thrombocytopenia (14.2) Reduction: 70 (19.7) Interruption: 124 (34.9) AEs adverse events, N/A no data available There are also significant toxicities associated with the use of mTOR pathway inhibition. Everolimus, evaluated in the BOLERO-2 trial, significantly improved PFS when added to exemestane. However, 19% of patients discontinued treatment because of toxicity, compared with 4% in the placebo group. The most common grade 3–4 toxicities were stomatitis, anemia, and hyperglycemia [75]. Significant stomatitis is often effectively prevented with a prophylactic dexamethasone mouthwash for patients on this therapy as demonstrated in the SWISH study [93]. Discussion and Conclusions Real-World Treatment Decisions Endocrine therapy combined with CDK4/6i is the standard first-line treatment for HR+/HER2– advanced breast cancer, but resistance commonly develops through ER-dependent (e.g., ESR1 mutations) and ER-independent (e.g., PI3K-AKT-mTOR pathway mutations) mechanisms. To address this, targeted therapies such as everolimus and alpelisib were approved based on trials showing PFS benefits [14, 77], although there was no benefit in OS. Adverse events such as stomatitis and hyperglycemia have impacted tolerability and limited the widespread clinical use of these targeted agents. Capivasertib, a pan-AKT inhibitor, was developed to overcome these challenges and received FDA approval following the CAPItello-291 trial. It offers a more favorable safety profile, lower rates of diarrhea and rash, and has been studied in a patient cohort with glycated hemoglobin ≥ 6.4% [67]. Most recently, inavolisib, a more potent PI3K inhibitor with a better therapeutic index, was FDA approved in 2024 for based on evidence from the INAVO-120 phase III trial in PIK3CA-mutated high-risk patients with disease recurrence while on or within 12 months of completion of adjuvant endocrine therapy. Inavolisib in combination with palbociclib and fulvestrant offer both PFS and OS benefits, which can serve as a new first-line treatment for locally advanced or metastatic disease with early relapse, post-adjuvant endocrine therapy [94]. In the second line setting, targeted therapy plays a major role. For patients with PIK3CA-mutated tumors, capivasertib or alpelisib with fulvestrant should be considered given their survival benefit as demonstrated in prospective studies. The authors prefer capivasertib over alpelisib as it is better tolerated with a smaller incidence of hyperglycemia. For tumors with AKT or PTEN alternations, capivasertib with fulvestrant could be considered. Olaparib or talazoparib is an attractive option for patients with germline BRCA1/2 mutations before initiation of chemotherapy. For patients with ESR1-mutated tumors, elacestrant should be considered second line if patients had a durable response to prior CDK4/6i (12 months or more). Imlunestrant monotherapy was also approved recently for the ESR1-mutated population in a similar setting given the PFS benefit that was demonstrated in EMBER-3 trial [95]. The advent of novel targeted therapies raises questions about optimal sequencing with oral targeted agents such as capivasertib and elacestrant, especially in the presence of co-mutations of ESR1 and PIK3CA. Treatment selection should take into consideration the patients’ medical comorbidities, durable response to treatment on CDK4/6i, and side-effect profile. For example, given that hyperglycemia is a frequent adverse effect of PI3K-AKT-mTOR pathway inhibitors, alternative agents such as elacestrant or imlunestrant may be preferred in patients with poorly controlled diabetes mellitus when actionable co‑mutated ESR1 and PIK3CA/AKT/PTEN alterations are identified. Other options include switching to a different selective ER degrader (i.e., fulvestrant) or abemaciclib plus fulvestrant based on the postMONARCH trial [96]. Figure 2 outlines our proposed treatment approach and Table 3 provides a treatment outcome comparison amongst currently available targeted therapies. Treatment approach for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) advanced breast cancer with PIK3CA mutations. AI aromatase inhibitor, CDK4/6i cyclin-dependent kinases 4 and 6 inhibitor, ET endocrine therapy, mos months, PARP poly ADP ribose polymerase. Figure was generated using BioRender software Table 3Treatment outcome with currently available second-line novel therapiesTarget mutationNovel agentCombination therapymPFS (months, HR, 95% CI)PIK3CAAlpelisibInavolisibFulvestrantPalbociclib + fulvestrant7.4 (0.65, 0.5–0.9) [14]15.0 (0.48, 0.3–0.6) [9]PIK3CA/AKT1/PTENCapivasertibEverolimusFulvestrantAromatase inhibitors7.3 (0.50, 0.4–0.7) [67]6.9 (0.43, 0.4–0.5) [75]ESR1ElacestrantImlunestrantNoNo26.8% (0.55, 0.4–0.8)a [103]5.5 (3.9–7.4)b [95]BRCA1/2OlaparibNo7.0 (0.58, 0.4–0.8) [104]CI confidence interval, HR hazard ratio, mPFS median progression-free survival, PFS progression-free survivala12-month PFS rate reported instead of mPFSbHR was not reported because non-proportional hazards could lead to misinterpretation Treatment outcome with currently available second-line novel therapies Alpelisib Inavolisib Fulvestrant Palbociclib + fulvestrant 7.4 (0.65, 0.5–0.9) [14] 15.0 (0.48, 0.3–0.6) [9] Capivasertib Everolimus Fulvestrant Aromatase inhibitors 7.3 (0.50, 0.4–0.7) [67] 6.9 (0.43, 0.4–0.5) [75] Elacestrant Imlunestrant No No 26.8% (0.55, 0.4–0.8)a [103] 5.5 (3.9–7.4)b [95] CI confidence interval, HR hazard ratio, mPFS median progression-free survival, PFS progression-free survival a12-month PFS rate reported instead of mPFS bHR was not reported because non-proportional hazards could lead to misinterpretation As triplet therapy (CDK4/6i, PI3Kα inhibitor, fulvestrant per INAVO120) gains more widespread use in the first-line setting, second-line treatment with a selective ER degrader plus a mTOR inhibitor as evaluated in the evERA study showed a PFS benefit of 8.8 months with giredestrant (selective ER degrader) and everolimus (mTOR inhibitor) compared with 5.5 months in the endocrine therapy plus everolimus control group. After progression on CDK4/6i, other second-line options include endocrine therapy with or without everolimus should be considered if the tumor is thought to be endocrine sensitive. A switch to ribociclib or abemaciclib plus fulvestrant is also reasonable if a patient progressed on prior palbociclib based on MAINTAIN [97] and postMONARCH [96] trials. However, for patients with rapid disease progression, reflective of endocrine-refractory disease, chemotherapy or an antibody drug conjugate is the best choice (See Table 4). Table 4Rising PI3K/AKT/mTOR agents for locally advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancerClassMechanism of actionAgentTrial (phase)Allostatic PI3K inhibitorBinds the mutation-induced cryptic pocket that is accessible only in mutant p110α conformations and therefore achieves mutant selectivityRLY-2608STX-478LOXO-783NCT05216432 (II) [87]NCT05768139 (I/II) [86]NCT05307705 (I) [57]Covalent PI3K inhibitorDual mechanism: 1. Occupies the ATP-binding site with > 300-fold selectivity for PI3Kα; 2. Induces selective proteasomal degradation of mutant p110α proteinTOS-358NCT05683418 (I) [88]Allosteric AKT1 inhibitorSelectively, covalently, and potently inhibits the AKT1 E17K variantALTA2618NCT06533059 (I) [89]Bi-steric mTORC1 inhibitorEngages both allosteric and orthosteric ATP-binding sites on mTOR to achieve both complete 4EBP1 (mTOR substrate) inhibition and high mTORC1 selectivity.RMC-5552NCT04774952 (I) [90]mTOR mammalian target of rapamycin, mTORC1 mammalian target of rapamycin complex 1, P13K phosphatidylinositol 3-kinase Rising PI3K/AKT/mTOR agents for locally advanced/metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer RLY-2608 STX-478 LOXO-783 NCT05216432 (II) [87] NCT05768139 (I/II) [86] NCT05307705 (I) [57] mTOR mammalian target of rapamycin, mTORC1 mammalian target of rapamycin complex 1, P13K phosphatidylinositol 3-kinase Future Directions of PIK3CA Inhibitor Therapies Several next-generation agents targeting the PI3K-AKT-mTOR pathway warrant close attention in upcoming studies. These include allosteric mutant-selective inhibitors of PI3Kα (RLY-2608, STX-478, and LOXO-783) [57, 86, 87], covalent PI3Kα inhibitors (TOS-358) [88], allosteric AKT1 E17K mutation-selective inhibitor (ALTA2618) [89], and bi-steric selective mTORC1 inhibitors (RMC-5552) [90, 91] as described above. Compared with earlier generations, these agents demonstrate enhanced specificity, potency, and improved safety profiles in preclinical models, positioning them as strong candidates for success in future phase II and III trials. Dual inhibitors such as gedatolisib, which simultaneously target all class I PI3K isoforms and both mTOR complexes, may further shift the therapeutic landscape, given encouraging early clinical data, although its use could be limited by the route of administration (intravenous). Another promising avenue involves combining PI3K-AKT-mTOR pathway inhibitors with an immune checkpoint blockade. The PI3K-AKT-mTOR pathway has been implicated in promoting an immunosuppressive tumor microenvironment through effects on regulatory T cells, myeloid-derived suppressor cells, and cytokine signaling [98]. Therefore, rationally designed combination strategies could synergistically enhance and prolong anti-tumor immune responses. Ongoing clinical evaluation includes the phase I/II MORPHEUS‑panBC trial (NCT03424005) and a phase Ib study (NCT03673787), which are currently enrolling patients to investigate atezolizumab in combination with ipatasertib in advanced solid tumors, including PIK3CA‑mutated HR+/HER2– breast cancer [99, 100]. Finally, the development of additional new endocrine therapies such as proteolysis-targeting chimeras (PROTACs) represents a novel strategy for overcoming limitations of traditional endocrine inhibitors. Unlike conventional agents that simply block enzymatic activity, PROTACs induce degradation of target proteins by hijacking the catalytic subunit of class I PI3K [101]. Recent work by Zhang et al. demonstrated that a PI3K-targeted PROTAC (ZM-PI05) successfully overcame lapatinib resistance in HER2+, PIK3CA-mutant breast cancer models [102]. These findings highlight the potential of PROTACs to address drug resistance and residual pathway signaling by fully eliminating key oncogenic proteins, thereby restoring sensitivity to other therapies and improving long-term outcomes. With ongoing advances in therapeutic development, patients with advanced HR+/HER2– breast cancer will soon have multiple targeted options to inhibit the PI3K pathway. Future efforts will focus on enhancing the therapeutic index and optimizing clinical efficacy, aiming to not only overcome resistance but also improve both survival and quality of life for patients whose disease is driven by PI3K pathway activation. Funding No external funding was used in the preparation of this article. Declarations Conflicts of interest/Competing interests Elizabeth Sakach: consulting or an advisory role: Stemline, AstraZeneca, and Novartis. Research funding (institution): Pfizer, Puma, Eli Lilly, Rayzebio, and ProDa. Kevin Kalinsky: spouse, stock: EQRX (prior employee) and ADC Therapeutics; consulting fees from Lilly, Novartis, Genentech/Roche, Gilead, Seattle Genetics, AstraZeneca, Daiichi Sankyo, Puma Biotechnology, Mersana, Menarini Silicon Biosystems, Myovant Sciences, Takeda, Prelude Therapeutics, eFFECTOR Therapeutis, Regor, RayzeBio, Relay Therapuetics, and Merck, and institutional funding from Novartis, Genentech/Roche, Lilly, Seattle Genetics, AstraZeneca, Daichi Sankyo, and Ascentage, all outside the submitted work. Shipra Gandhi: consulting: Hologic, AstraZeneca, Novartis, MedPage Today, Genentech, Stemline Therapeutics; honorarium: OncLive, Aptitude Health, Clinical Care Options, and PeerView; speaker: Roche. Lan Lei, Madison Canning, Almeera Lateef, Larisa Kamga, and Minaam Abid have no conflicts of interest that are directly relevant to the content of this article. Ethics Approval Not applicable. Consent to Participate Not applicable. Consent for Publication Not applicable. Availability of Data and Material Not applicable. Code Availability Not applicable. Authors’ Contributions Conceptualization: SG and KK designed the scope and structure of the review. Data curation: LL collected and organized the literature sources. Writing (original draft): LL, MC, ES, AL, LK, MA. Writing (review and editing): ES, KK, SG. References